RETRACTABLE TECHNOLOGIES INC

The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating minimal leverage. Its liquidity position is supported by $2.77 million in cash and equivalents, with a current ratio of 5.74, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of $1.37 million and free cash flow of $1.37 million, reflecting ongoing operational challenges. Profitability metrics are weak, with a net loss of $4.23 million and a return on equity of -6.03%. The company's return on assets of -3.07% further underscores its underperformance relative to industry norms. Gross profit was negative at $838,409, indicating significant cost pressures. These figures are below the industry median for medical device manufacturers, which typically report positive gross margins and higher returns on equity. The company's revenue is concentrated in a few key segments, with a significant portion derived from the sale of safety syringes and related products. Geographically, the company operates primarily in the United States, with limited international exposure. The company's reliance on a narrow product portfolio and domestic market increases its vulnerability to market fluctuations and regulatory changes. The company's growth trajectory is constrained by its current financial performance. Revenue for Q1 2026 was $7.18 million, a decline from the previous year. The outlook for the current fiscal year is negative, with no significant revenue growth expected. The company's ability to maintain liquidity and manage its debt obligations will be critical to its future performance. Risk factors include the company's negative cash flow and net loss, which could impact its ability to fund operations and invest in growth. The company has a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's reliance on a narrow product portfolio and domestic market increases its exposure to market and regulatory risks. Recent events include the company's continued focus on domestic manufacturing capacity for vaccine administration products, funded in part by the Technology Investment Agreement with the U.S. Department of Defense. The company also reported an inventory obsolescence adjustment of $863,037 for Q1 2026, compared to no material write-downs in the same period in 2025. These adjustments reflect management's assessment of inventory levels and market conditions.